Celgene Corp. (CELG)

90.20
NASDAQ : Health Technology
Prev Close 90.91
Day Low/High 90.08 / 90.99
52 Wk Low/High 58.59 / 98.97
Avg Volume 4.59M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 64.12B
EPS 5.70
P/E Ratio 13.88
Div & Yield N.A. (N.A)
No Shortage of Market Negatives

No Shortage of Market Negatives

The longer we go without much progress, the more inclined players are to move to the sidelines.

The Level of Negativity in the Market Is Finally Building

The Level of Negativity in the Market Is Finally Building

This is what we need to stop treading water and move this market to a tradable low.

My Takeaways and Observations

 A short "Takeaways" today as I have to prepare for some morning meetings.   Down, up, down -- in a relatively volatile session.   I am comfortable with yesterday's bearish moves.    I sold more (short) today on the surprising (at least to me!) ramp...

My Takeaways and Observations (Early Edition)

Don't get excited by Take Under Monday.   The technical picture is mixed.    A stronger U.S. dollar presents multi-national vulnerability. This is consistent with Goldman Sachs lowering their three-year S&P 500 profits picture.    Peak Sports Viewer...

Pharma Should Offer Post-Election Bargains

Pharma Should Offer Post-Election Bargains

The likely continuation of a split government should help the sector recover from its recent beat-down.

Biotech Bargain Bin Bursts With Bounty

Biotech Bargain Bin Bursts With Bounty

This sector is one of the few areas of the market where you'll find myriad compelling values.

Why Celgene Is a Core Biotech Holding

Why Celgene Is a Core Biotech Holding

Celgene's days of stellar growth will continue to stretch far into the future.

My Takeaways and Observations

"And when I see the sign that points one way The lot we used to pass by every day Just walk away Renee You won't see me follow you back home The empty sidewalks on my block are not the same You're not to blame." -- Left Banke, Walk Away Renee Renee ...

A Moment of Truth Is Approaching on Celgene

A Moment of Truth Is Approaching on Celgene

A close below $95 is likely to precipitate further short-term declines.

It's Not Easy Being Green: 3 Solid Names That Stand Out

It's Not Easy Being Green: 3 Solid Names That Stand Out

Look for solid companies showing life.

My Takeaways and Observations

The media is not the message. With a little help from Johnny Mercer, did you know he founded Capitol Records?   This is serious folks -- I see less of a reason to have an outsized long portfolio than at any time since Winter 2007. The market outlook...

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

On days like this, the money just keeps sloshing around.

3 Stocks for Growth in 2017

3 Stocks for Growth in 2017

BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.

My Takeaways and Observations

It was a nostalgic morning. A 20th anniversary.  My first TST column in 1997.  There was no rest for the weary as the crude and oil markets turned on a dime after OPEC announced a production cut. I, Jim Cramer and others are skeptical about this - s...

A Good Day to be Short

My Takeaways and Observations   A good day for the dark side.   Sell in September or Get Dismembered (Part Trois!). Those bulls who were self-confident last Wednesday couldn't be seen today ... or Friday. Predictable.   Regardless of the winner, my ...

5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

Agios Shares Spike on Planned Drug Application

Agios Shares Spike on Planned Drug Application

The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Today's Takeaways and Observations

Another snore fest today. The widening disconnect between stock prices and the real economy.  Mark Hanson on the disappointing housing data today. Thus far, Apple short (calls) --my Trade of the Week -- are doing well. At $10 I added J.C. Penney to ...

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

Housing, Biotech Offer Affordable Growth

Housing, Biotech Offer Affordable Growth

These sectors offer value as the S&P 500 trades at 19x earnings.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Today's Good, Bad and Ugly

"Two hundred thousand dollars is a lot of money. We're gonna have to earn it." --Blondie, "The Good, The Bad and The Ugly" Let's look at the good, the bad and the ugly (my new daily feature) so far in today's trading session: The Good Biotech is dan...

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Celgene Has a $125 Price Target

Celgene Has a $125 Price Target

We can see the impressive reversal in the share price